Application of telithromycin in anti-ebola-virus infection

A technology of Ebola virus and telithromycin, applied in the field of medicine, can solve the problems such as no report on anti-Ebola virus effect, no report on antiviral activity of azithromycin and telithromycin, etc.

Active Publication Date: 2019-05-03
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After searching, there is no report on the antiviral activity of azithromycin and telithromycin, and no report on the anti-Ebola virus effect of these two drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of telithromycin in anti-ebola-virus infection
  • Application of telithromycin in anti-ebola-virus infection
  • Application of telithromycin in anti-ebola-virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1. Principle of Screening Model

[0043] The entry of Ebola virus into the host cell is the first step of virus infection, and inhibiting the entry of the virus can effectively block the virus infection. The glycoprotein (Glycoprotein, GP) on the surface of EBV envelope is the key protein in the process of EBV entry.

[0044] We synthesized the envelope GP gene of Zaire type Ebola virus (EBV-Zaire GP, Gene Accession No. L11365). By co-transfection of EBV-GP plasmid and pNL4-3-Luc-R - E. - , EBV recombinant virus EBV-GP / HIV with EBV-GP as the outer shell wrapping the HIV core can be obtained [16] . The virus particle has the following characteristics: 1) The selectivity of the virus to the host cell depends on the characteristics of EBV GP; 2) Due to the deletion of env, nef and vpr genes on the HIV vector, the virus can only enter the host cell once and cannot replicate , so the virus is safe; 3) the HIV vector has a luciferase reporter gene, so the infecte...

Embodiment 2

[0045] Embodiment 2. Experimental method

[0046] In the present invention, EBV-Zaire (Gene Accession No.L11365) is used to evaluate the pharmacological activity of azithromycin and telithromycin against Ebola virus infection:

[0047] Recombinant virus preparation [16] : Co-transfect 2 μg pcDNA3.1 / EBV-GP plasmid and 2 μg pNL4-3-Luc-R - E. - Put the plasmid into 293T cells, collect the supernatant 48 hours after transfection, and filter the supernatant through a 0.45 μm filter membrane. The supernatant contains EBV-GP / HIV virus particles, and the recombinant virus can be used for infection. Prepare VSV-G / HIV recombinant virus in the same way.

[0048] Infect [16] : One day before infection, press 6×10 per well 4 A549 cells were seeded on a 24-well plate at a density of 1 cell. The positive control compound or the compound to be screened was dissolved in DMSO, and added to the cell culture medium 15 minutes before infection, and the DMSO solvent was used as a blank contro...

Embodiment 3

[0051] Example 3. Cytotoxicity test

[0052] The cytotoxicity of all involved drugs to A549 and 293ET cells was measured by MTS method, and the results showed that neither azithromycin nor telithromycin had cytotoxicity at a final concentration of 10 μM.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of azithromycin and telithromycin in anti-ebola-virus infection, including application of azithromycin or / and telithromycin in prevention or treatment of ebola virus infection or combined application of azithromycin or / and telithromycin with other anti-virus drugs.

Description

technical field [0001] The invention relates to the application of azithromycin and telithromycin in resisting Ebola virus infection, and belongs to the technical field of medicine. Background technique [0002] Ebola hemorrhagic fever (Ebola hemorrhagic fever, EHF) is caused by Ebola virus (EBV), is a major severe infectious disease that seriously endangers public safety and human health, and the fatality rate is as high as 50%-90%. [1] . The Ebola virus can be transmitted from person to person through contact and air droplets, and is listed as a class A biological weapon [2] . [0003] Since the Ebola virus was first discovered in 1976, it has caused 11 large-scale outbreaks. In April 2014, a new round of Ebola hemorrhagic fever outbreaks broke out in Guinea and Liberia. As of August 11, 2014, 1975 outbreaks have been confirmed. people infected, 1069 of whom died [3] . The clinical manifestations of Ebola virus are acute onset, high fever, headache, myalgia, multiple ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/706A61K31/7052A61P31/14
Inventor 郭颖陈勍霸明宇王丽丽
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap